adjuvant therapies for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 hospitalized meta-analysis
Paranjpe		OBS	anticoagulant	control	COVID 19 hospitalized	critical	786/1987	no results	the primary result seems inconclusive (no p value given, but in-hospital mortality for AC was 22.5% with a median survival of 21 days, compared to 22.8% and median survival of 14 days in control group)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 hospitalized meta-analysis